US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acrivon Therapeutics, Inc.

1.81

-0.0400-2.16%

Post-market: 1.79-0.0200-1.10%19:58 EDT

Volume:236.49K

Turnover:418.45K

Market Cap:56.75M

PE:-0.76

High:1.87

Open:1.85

Low:1.66

Close:1.85

Loading ...

Overview Company News Filings

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics Names Dr. Mirza as Medical Chief

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief

MT Newswires Live

Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer

Press Release: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

BUZZ-Maxim cuts Acrivon PT on deprioritization of ovarian and bladder programs

Acrivon Therapeutics Inc : Maxim Group Cuts Target Price to $7 From $24

THOMSON REUTERS

Acrivon Therapeutics Inc : Jefferies Cuts Target Price to $14 From $18

THOMSON REUTERS

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Acrivon Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Acrivon Therapeutics, Inc Q4 Income From Operations USD -24.954 Million

Press Release: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics Inc - Q4 Shr Loss $0.60

THOMSON REUTERS

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings

Acrivon Therapeutics Price Target Maintained With a $17.00/Share by Citizens Capital Markets

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical Acr-368 and Acr-2316 Program Updates

THOMSON REUTERS

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics announces FDA granted BDD for ACR-368

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACRV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACRV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","market":"US","secType":"STK","nameCN":"Acrivon Therapeutics, Inc.","latestPrice":1.81,"timestamp":1744920000000,"preClose":1.85,"halted":0,"volume":236493,"hourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.81,"latestTime":"19:58 EDT","volume":1895,"amount":3506.95,"timestamp":1744934314424},"delay":0,"floatShares":11274481,"shares":31351480,"eps":-2.38389,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-17 16:00:00 EDT","open":1.85,"high":1.87,"low":1.66,"amount":418454.78187959996,"amplitude":0.113514,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.38389,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1668488400000,"exchange":"NASDAQ","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.86,"preClose":1.85,"latestTime":"09:29 EDT","volume":4396,"amount":8137.749914,"timestamp":1744896599907},"postHourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.81,"latestTime":"19:58 EDT","volume":1895,"amount":3506.95,"timestamp":1744934314424},"volumeRatio":0.44025809390345644},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","floatShares":11274481,"roa":"-33.30%","roe":"-54.07%","lyrEps":-2.38389,"volumeRatio":0.44025809390345644,"shares":31351480,"dividePrice":0,"high":1.87,"amplitude":0.113514,"preClose":1.85,"low":1.66,"week52Low":1.3,"pbRate":"0.32","week52High":11.51,"institutionHeld":0,"latestPrice":1.81,"eps":-2.38389,"divideRate":0,"volume":236493,"delay":0,"ttmEps":-2.38389,"open":1.85,"prevYearClose":6.02,"prevWeekClose":1.62,"prevMonthClose":2.03,"prevQuarterClose":2.03,"fiveDayClose":1.53,"twentyDayClose":5.14,"sixtyDayClose":5.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACRV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527191300","title":"Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527191300","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527191300?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:35","pubTimestamp":1744637704,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics, Inc.  has been beaten down lately with too much selling pressure. While the stock has lost 70.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The heavy selling of ACRV shares appears to be in the process of exhausting itself, as indicated by its RSI readin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/down-70-22-4-weeks-133504895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4150","ACRV","BK4139","RSI"],"gpt_icon":1},{"id":"2525307713","title":"Acrivon Therapeutics Names Dr. Mirza as Medical Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2525307713","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525307713?lang=en_us&edition=fundamental","pubTime":"2025-04-08 06:14","pubTimestamp":1744064040,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics has appointed Dr. Mansoor Raza Mirza as chief medical officer, effective Wednesday.Dr. Mirza joins the Watertown, Mass. clinical stage precision medicine company from Denmark's Copenhagen University National Medical Center, where he served as chief oncologist, Acrivon said Monday.Mirza succeeds Dr. Jean-Marie Cuillerot, who entered the role in January of last year.Mirza brings decades of clinical research and patient care experience, and specializes in gynecologic malignancies, or cancers affecting female reproductive organs, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ACRV","LENZ"],"gpt_icon":0},{"id":"2525746190","title":"Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2525746190","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525746190?lang=en_us&edition=fundamental","pubTime":"2025-04-08 05:13","pubTimestamp":1744060393,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics (ACRV) said Monday it appointed Mansoor Mirza as chief medical officer, starting from April 9, succeeding Jean-Marie Cuillerot.Shares of the company were up more than 4% in recent after-hours activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRV","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2525441076","title":"Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525441076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525441076?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:11","pubTimestamp":1744056709,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics (ACRV) announced that Mansoor Raza Mirza, M.D., has been appointed Chief Medical Officer of the company, effective April 9. Wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acrivon-appoints-mansoor-raza-mirza-as-chief-medical-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acrivon-appoints-mansoor-raza-mirza-as-chief-medical-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2525076327","title":"Press Release: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076327","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076327?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:05","pubTimestamp":1744056300,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer. Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades. Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types. \"We are thrilled that Mansoor is joining us at this exciting time for the company,\" said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. \"Mansoor is globally recognized for his groundbreaking contributions to the clinical development of novel ovarian and endometrial cancer therapies, and we look forwa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","ACRV","BK4139"],"gpt_icon":0},{"id":"2524010191","title":"BUZZ-Maxim cuts Acrivon PT on deprioritization of ovarian and bladder programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524010191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524010191?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505257,"startTime":"0","endTime":"0","summary":"BUZZ-Maxim cuts Acrivon PT on deprioritization of ovarian and bladder programs** Maxim Group cuts PT on drug developer Acrivon Therapeutics ACRV.O to $7 from $24** Cites deprioritization of ovarian and bladder programs** \"Management announced that due to a higher bar in ovarian cancer and difficulty recruiting OncoSignature positive patients in bladder cancer, the company is deprioritizing these programs,\" says brokerage** Adds the data in endometrial cancer is still quite strong and with a positive safety profile** New PT is ~245% upside to stock's last close** Nine of 10 brokerages rate stock \"buy\" or higher, and 1 \"hold\"; median PT is $15 - data compiled by LSEG** ACRV shares down ~66% YTD, as of last close; they rose ~22% in 2024   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL6N3QF0JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2524713318","title":"Acrivon Therapeutics Inc : Maxim Group Cuts Target Price to $7 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2524713318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524713318?lang=en_us&edition=fundamental","pubTime":"2025-04-01 11:26","pubTimestamp":1743477965,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QE17B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2523780962","title":"Acrivon Therapeutics Inc : Jefferies Cuts Target Price to $14 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2523780962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523780962?lang=en_us&edition=fundamental","pubTime":"2025-03-31 15:41","pubTimestamp":1743406905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2523685576","title":"Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685576","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685576?lang=en_us&edition=fundamental","pubTime":"2025-03-29 00:00","pubTimestamp":1743177608,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Acrivon Therapeutics, Inc. , as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Therefore, the Zacks rating upgrade for Acrivon Therapeutics, Inc. basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Acrivon Therapeutics, Inc. imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.This company is expected to earn -$2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-inc-acrv-upgraded-160008685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACRV"],"gpt_icon":0},{"id":"2522652432","title":"Acrivon Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522652432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522652432?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:53","pubTimestamp":1743159180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 06:53 ET (10:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","LENZ"],"gpt_icon":0},{"id":"2522582595","title":"Acrivon Therapeutics, Inc Q4 Income From Operations USD -24.954 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522582595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522582595?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:01","pubTimestamp":1743112904,"startTime":"0","endTime":"0","summary":"Mar 27 (Reuters) - Acrivon Therapeutics, Inc Q4 operating expenses USD 24.954 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-MAR-202521:40:00.063 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nRSD5kjW68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2522530052","title":"Press Release: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522530052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522530052?lang=en_us&edition=fundamental","pubTime":"2025-03-28 05:44","pubTimestamp":1743111840,"startTime":"0","endTime":"0","summary":"Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects. R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily pretreated aggressive tumors, and who had all progressed on prior anti-PD-1 and chemotherapy, with 35% confirmed overall response rate , which is >2-fold higher than last prior line of therapy (15%). In the BM+ patients who had relapsed after prior anti-PD-1 and chemotherapy, the cORR was 50% with the median duration of response  not yet reached , while in BM+ patients who were refractory to their last prior line of therapy, the cORR was 33% and mDOR was 3.4 months","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACRV","BK4139"],"gpt_icon":0},{"id":"2522532879","title":"Acrivon Therapeutics Inc - Q4 Shr Loss $0.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532879?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:50","pubTimestamp":1743108626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1I9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2522387694","title":"Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387694","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387694?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:28","pubTimestamp":1743006506,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44498176/crude-oil-gains-over-1-cintas-shares-jump-after-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","WOR","OSRH","ICG","ACON","CTAS","VVPR"],"gpt_icon":0},{"id":"2522805787","title":"Acrivon Therapeutics Price Target Maintained With a $17.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805787?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:10","pubTimestamp":1742994600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:10 ET (13:10 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACRV"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THRD","PAYS","SDST","BEEM","RVPH","FBIO","PDSB","DERM","MREO","CNXC","BCAB","WOOF","LPTX","SCS","IKT","XFOR","SURG","ANTX","MLKN","PAYX","OBIO","ACRV","GOVX","MKC","CALC","WBA","AFMD","WGO","NUTX","CRMD","SKYX","EDAP","SLRN","RLMD","CDLR","GRDN","MDAI","KOD","IVA","ABL","IOBT","CLSD","CTAS","KBH","DLTR","UNCY","ZURA","CHWY","ALUR","TEN"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLC","TH","JKS","DRI","BLRX","TELA","PAYX","PL","RLMD","SOWG","TITN","WOR","MNSO","OUST","SKYE","SBS","ALUR","NKE","MLKN","GDEV","ASO","CELC","MGNX","MBRX","CDLR","BCAB","MREO","LVTX","JEF","BBNX","ACRV","THRD","SLS","DERM","RUM","BRAG","SPRY","CMC","LPTX","LEN","BRNS","CBUS","FBRX","IFRX","NKTX","FLUX","CURV","COYA"],"gpt_icon":1},{"id":"2520713188","title":"Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical Acr-368 and Acr-2316 Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520713188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520713188?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA1ZHGFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2520185764","title":"Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520185764","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520185764?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385600,"startTime":"0","endTime":"0","summary":"Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET. To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner yielding terabytes of high resolution proprietary quantitative data for pathway-based drug design, indication finding, and response prediction. These distinctive capabilities enable AP3’s direct application for streamlined rati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-host-corporate-r-120000156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACRV","HST","BK4181","BK4218","LENZ","ACR","BK4110","GCIG","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2509275558","title":"Acrivon Therapeutics announces FDA granted BDD for ACR-368","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275558","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275558?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:16","pubTimestamp":1738847797,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics  announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment. The designation reflects the FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection.Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  Your Smart Portfolio. Acrivo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACRV","BDD","ACR","LENZ","BK4110","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACRV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"ACRV","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACRV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACRV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.7,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1738382400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACRV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACRV","date":"2025-04-17","current":-0.719999,"percent":0.982639,"low":-18.228389,"twenty":-8.116132,"median":-3.63581,"eighty":-2.239145,"high":-0.529297,"avg":-5.395957,"sd":4.088552,"marketCap":58000238},"quantilePoints":[{"date":"2022-11-11","current":-11.86111,"twenty":-16.13111,"median":-16.13111,"eighty":-13.56911,"marketCap":235122787},{"date":"2022-11-18","current":-16.605358,"twenty":-17.148347,"median":-16.336664,"eighty":-13.56911,"marketCap":329168006},{"date":"2022-11-25","current":-13.1538,"twenty":-16.59273,"median":-14.65824,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-02","current":-13.311646,"twenty":-16.459997,"median":-13.18537,"eighty":-13.1538,"marketCap":263876760},{"date":"2022-12-09","current":-13.1538,"twenty":-16.13111,"median":-13.18537,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-16","current":-9.42062,"twenty":-15.609309,"median":-13.164324,"eighty":-13.1538,"marketCap":250409495},{"date":"2022-12-23","current":-9.15348,"twenty":-13.492642,"median":-13.1538,"eighty":-9.908718,"marketCap":243308642},{"date":"2022-12-30","current":-9.051338,"twenty":-13.374784,"median":-13.1538,"eighty":-9.15348,"marketCap":240593610},{"date":"2023-01-06","current":-9.114194,"twenty":-13.324274,"median":-13.1538,"eighty":-9.10948,"marketCap":242264399},{"date":"2023-01-13","current":-9.758474,"twenty":-13.286391,"median":-13.1538,"eighty":-9.096909,"marketCap":259389986},{"date":"2023-01-20","current":-11.102032,"twenty":-13.261136,"median":-11.86111,"eighty":-9.107908,"marketCap":295103100},{"date":"2023-01-27","current":-11.416314,"twenty":-13.210625,"median":-11.432028,"eighty":-9.118908,"marketCap":303457044},{"date":"2023-02-03","current":-14.967707,"twenty":-13.261136,"median":-11.549884,"eighty":-9.140908,"marketCap":397856621},{"date":"2023-02-10","current":-17.254113,"twenty":-13.707494,"median":-12.294777,"eighty":-9.280764,"marketCap":458631569},{"date":"2023-02-17","current":-16.963401,"twenty":-16.209458,"median":-13.1538,"eighty":-9.39862,"marketCap":450904170},{"date":"2023-02-24","current":-12.044879,"twenty":-16.13111,"median":-12.885585,"eighty":-9.423763,"marketCap":320164934},{"date":"2023-03-03","current":-16.499835,"twenty":-16.177918,"median":-13.1538,"eighty":-9.434763,"marketCap":438582102},{"date":"2023-03-10","current":-15.745556,"twenty":-16.430693,"median":-13.1538,"eighty":-9.447334,"marketCap":418532634},{"date":"2023-03-17","current":-15.714128,"twenty":-16.525265,"median":-13.1538,"eighty":-9.527476,"marketCap":417697240},{"date":"2023-03-24","current":-10.229897,"twenty":-16.430693,"median":-13.1538,"eighty":-9.461476,"marketCap":271920903},{"date":"2023-03-31","current":-8.928026,"twenty":-16.282979,"median":-13.1538,"eighty":-9.434763,"marketCap":278259784},{"date":"2023-04-06","current":-7.274688,"twenty":-16.215409,"median":-13.019693,"eighty":-9.37662,"marketCap":226730194},{"date":"2023-04-14","current":-6.723819,"twenty":-16.19352,"median":-12.044879,"eighty":-9.115765,"marketCap":209561261},{"date":"2023-04-21","current":-8.060143,"twenty":-16.13111,"median":-11.86111,"eighty":-9.056052,"marketCap":251210465},{"date":"2023-04-28","current":-8.650938,"twenty":-16.126284,"median":-11.549884,"eighty":-9.035624,"marketCap":269623798},{"date":"2023-05-05","current":-7.956584,"twenty":-16.088124,"median":-11.377028,"eighty":-8.91982,"marketCap":247982856},{"date":"2023-05-12","current":-8.118522,"twenty":-16.003268,"median":-11.21203,"eighty":-8.835959,"marketCap":297974095},{"date":"2023-05-19","current":-7.88554,"twenty":-15.962411,"median":-10.807392,"eighty":-8.673871,"marketCap":289422962},{"date":"2023-05-26","current":-7.467367,"twenty":-15.908983,"median":-10.229897,"eighty":-8.438641,"marketCap":274074775},{"date":"2023-06-02","current":-7.419576,"twenty":-15.745556,"median":-9.829187,"eighty":-8.257075,"marketCap":272320696},{"date":"2023-06-09","current":-7.353863,"twenty":-15.714128,"median":-9.671273,"eighty":-8.064756,"marketCap":269908838},{"date":"2023-06-16","current":-7.138803,"twenty":-14.967707,"median":-9.475619,"eighty":-7.88554,"marketCap":262015484},{"date":"2023-06-23","current":-7.694375,"twenty":-14.936279,"median":-9.444191,"eighty":-7.691985,"marketCap":282406648},{"date":"2023-06-30","current":-7.957226,"twenty":-14.607853,"median":-9.4246,"eighty":-7.737387,"marketCap":292054080},{"date":"2023-07-07","current":-6.962573,"twenty":-14.230714,"median":-9.36562,"eighty":-7.687206,"marketCap":255547320},{"date":"2023-07-14","current":-7.312046,"twenty":-13.800187,"median":-9.122051,"eighty":-7.479315,"marketCap":268374019},{"date":"2023-07-21","current":-7.795931,"twenty":-13.463178,"median":-9.09848,"eighty":-7.467367,"marketCap":286134065},{"date":"2023-07-28","current":-7.335941,"twenty":-13.349529,"median":-9.063123,"eighty":-7.467367,"marketCap":269251058},{"date":"2023-08-04","current":-7.049195,"twenty":-13.305332,"median":-9.04741,"eighty":-7.451835,"marketCap":258726587},{"date":"2023-08-11","current":-6.929717,"twenty":-13.273763,"median":-9.035624,"eighty":-7.414797,"marketCap":254341391},{"date":"2023-08-18","current":-5.439761,"twenty":-13.23588,"median":-8.933664,"eighty":-7.374175,"marketCap":243684992},{"date":"2023-08-25","current":-5.824092,"twenty":-13.18537,"median":-8.917768,"eighty":-7.335941,"marketCap":260901867},{"date":"2023-09-01","current":-5.774819,"twenty":-13.181161,"median":-8.846512,"eighty":-7.295319,"marketCap":258694575},{"date":"2023-09-08","current":-5.764965,"twenty":-13.164324,"median":-8.810263,"eighty":-7.252307,"marketCap":258253117},{"date":"2023-09-15","current":-5.415125,"twenty":-13.164324,"median":-8.657972,"eighty":-7.138803,"marketCap":242581346},{"date":"2023-09-22","current":-4.666172,"twenty":-13.15801,"median":-8.650938,"eighty":-7.070701,"marketCap":209030514},{"date":"2023-09-28","current":-4.848483,"twenty":-13.1538,"median":-8.470778,"eighty":-7.024104,"marketCap":217197493},{"date":"2023-10-06","current":-3.606798,"twenty":-13.1538,"median":-8.337045,"eighty":-6.962573,"marketCap":161573745},{"date":"2023-10-13","current":-3.074648,"twenty":-13.1538,"median":-8.233741,"eighty":-6.723819,"marketCap":137734995},{"date":"2023-10-20","current":-2.670607,"twenty":-13.1538,"median":-8.118522,"eighty":-6.217422,"marketCap":119635204},{"date":"2023-10-27","current":-2.498151,"twenty":-13.1538,"median":-8.106574,"eighty":-6.135872,"marketCap":111909684},{"date":"2023-11-03","current":-2.650898,"twenty":-13.1538,"median":-8.060143,"eighty":-5.913769,"marketCap":118752288},{"date":"2023-11-10","current":-2.023663,"twenty":-13.1538,"median":-7.990082,"eighty":-5.83986,"marketCap":101314684},{"date":"2023-11-17","current":-1.968296,"twenty":-13.1538,"median":-7.956584,"eighty":-5.774819,"marketCap":98542723},{"date":"2023-11-24","current":-1.70231,"twenty":-13.1538,"median":-7.867618,"eighty":-5.710764,"marketCap":85226138},{"date":"2023-12-01","current":-1.795405,"twenty":-12.885585,"median":-7.837749,"eighty":-5.538308,"marketCap":89886943},{"date":"2023-12-08","current":-2.38944,"twenty":-12.728444,"median":-7.795931,"eighty":-5.434834,"marketCap":119627314},{"date":"2023-12-15","current":-2.220982,"twenty":-12.181592,"median":-7.694375,"eighty":-5.139195,"marketCap":111193478},{"date":"2023-12-22","current":-2.158919,"twenty":-11.988308,"median":-7.676453,"eighty":-4.765704,"marketCap":108086275},{"date":"2023-12-29","current":-2.207683,"twenty":-11.903452,"median":-7.658532,"eighty":-4.607044,"marketCap":110527648},{"date":"2024-01-05","current":-2.061391,"twenty":-11.878047,"median":-7.57191,"eighty":-4.424734,"marketCap":103203527},{"date":"2024-01-12","current":-2.136753,"twenty":-11.86111,"median":-7.467367,"eighty":-3.380635,"marketCap":106976559},{"date":"2024-01-19","current":-1.928398,"twenty":-11.771191,"median":-7.467367,"eighty":-3.021433,"marketCap":96545235},{"date":"2024-01-26","current":-1.795405,"twenty":-11.601741,"median":-7.461393,"eighty":-2.812514,"marketCap":89886943},{"date":"2024-02-02","current":-1.711176,"twenty":-11.509027,"median":-7.449445,"eighty":-2.678491,"marketCap":85670025},{"date":"2024-02-09","current":-1.569317,"twenty":-11.435171,"median":-7.416589,"eighty":-2.525448,"marketCap":78567846},{"date":"2024-02-16","current":-1.773239,"twenty":-11.384886,"median":-7.389706,"eighty":-2.417812,"marketCap":88777228},{"date":"2024-02-23","current":-1.693444,"twenty":-11.315743,"median":-7.371785,"eighty":-2.305211,"marketCap":84782252},{"date":"2024-03-01","current":-2.154486,"twenty":-11.224602,"median":-7.341915,"eighty":-2.222755,"marketCap":107864332},{"date":"2024-03-08","current":-2.274179,"twenty":-11.19003,"median":-7.329968,"eighty":-2.220982,"marketCap":113856794},{"date":"2024-03-15","current":-2.247581,"twenty":-11.059604,"median":-7.297111,"eighty":-2.213003,"marketCap":112525136},{"date":"2024-03-22","current":-2.806151,"twenty":-10.856891,"median":-7.272415,"eighty":-2.217436,"marketCap":140489963},{"date":"2024-03-28","current":-2.376071,"twenty":-10.724892,"median":-7.222437,"eighty":-2.220982,"marketCap":143486194},{"date":"2024-04-05","current":-2.507803,"twenty":-10.284897,"median":-7.147764,"eighty":-2.220982,"marketCap":151441202},{"date":"2024-04-12","current":-3.482435,"twenty":-10.229897,"median":-7.085038,"eighty":-2.220982,"marketCap":210297274},{"date":"2024-04-19","current":-5.388706,"twenty":-10.049185,"median":-7.03426,"eighty":-2.229848,"marketCap":325413151},{"date":"2024-04-26","current":-4.330392,"twenty":-9.829187,"median":-6.98405,"eighty":-2.238715,"marketCap":261503737},{"date":"2024-05-03","current":-4.325468,"twenty":-9.758474,"median":-6.941664,"eighty":-2.247581,"marketCap":261206357},{"date":"2024-05-10","current":-4.161857,"twenty":-9.701929,"median":-6.723819,"eighty":-2.252014,"marketCap":251326211},{"date":"2024-05-17","current":-4.122189,"twenty":-9.640618,"median":-6.484687,"eighty":-2.274179,"marketCap":264306537},{"date":"2024-05-24","current":-3.905485,"twenty":-9.530619,"median":-6.182256,"eighty":-2.300778,"marketCap":250411918},{"date":"2024-05-31","current":-3.645441,"twenty":-9.486619,"median":-5.962057,"eighty":-2.304324,"marketCap":233738375},{"date":"2024-06-07","current":-3.534681,"twenty":-9.456762,"median":-5.903338,"eighty":-2.319397,"marketCap":226636680},{"date":"2024-06-14","current":-3.717675,"twenty":-9.447334,"median":-5.87583,"eighty":-2.333583,"marketCap":238369915},{"date":"2024-06-21","current":-3.139798,"twenty":-9.437905,"median":-5.82902,"eighty":-2.354834,"marketCap":201317596},{"date":"2024-06-28","current":-2.77381,"twenty":-9.43162,"median":-5.804383,"eighty":-2.368992,"marketCap":177851128},{"date":"2024-07-05","current":-2.956804,"twenty":-9.426151,"median":-5.774819,"eighty":-2.384092,"marketCap":189584362},{"date":"2024-07-12","current":-3.809173,"twenty":-9.422212,"median":-5.764965,"eighty":-2.38944,"marketCap":244236532},{"date":"2024-07-15","current":-3.587653,"twenty":-9.421416,"median":-5.737865,"eighty":-2.38944,"marketCap":230033143},{"date":"2024-08-02","current":-3.761016,"twenty":-9.42062,"median":-5.710764,"eighty":-2.38944,"marketCap":241148838},{"date":"2024-08-09","current":-3.457631,"twenty":-9.36562,"median":-5.60729,"eighty":-2.424905,"marketCap":221696371},{"date":"2024-08-16","current":-3.24525,"twenty":-9.15348,"median":-5.484107,"eighty":-2.429083,"marketCap":223928738},{"date":"2024-08-23","current":-3.900584,"twenty":-9.122051,"median":-5.437297,"eighty":-2.46037,"marketCap":269148096},{"date":"2024-08-30","current":-4.479612,"twenty":-9.122051,"median":-5.415125,"eighty":-2.496557,"marketCap":309102186},{"date":"2024-09-06","current":-3.617803,"twenty":-9.115765,"median":-5.286083,"eighty":-2.497832,"marketCap":249635633},{"date":"2024-09-13","current":-4.147456,"twenty":-9.101623,"median":-5.11,"eighty":-2.502093,"marketCap":286182786},{"date":"2024-09-20","current":-3.406839,"twenty":-9.092194,"median":-4.912887,"eighty":-2.503998,"marketCap":235078717},{"date":"2024-09-27","current":-3.258716,"twenty":-9.078052,"median":-4.882395,"eighty":-2.504606,"marketCap":224857903},{"date":"2024-10-04","current":-3.092638,"twenty":-9.056052,"median":-4.848483,"eighty":-2.507183,"marketCap":213398203},{"date":"2024-10-11","current":-3.133035,"twenty":-9.051338,"median":-4.755636,"eighty":-2.507803,"marketCap":216185697},{"date":"2024-10-18","current":-3.53252,"twenty":-9.045052,"median":-4.647577,"eighty":-2.523053,"marketCap":243750922},{"date":"2024-10-25","current":-3.604337,"twenty":-9.037195,"median":-4.514034,"eighty":-2.551196,"marketCap":248706468},{"date":"2024-10-31","current":-3.747972,"twenty":-9.035624,"median":-4.481789,"eighty":-2.572061,"marketCap":258617561},{"date":"2024-11-08","current":-3.815301,"twenty":-8.97914,"median":-4.409952,"eighty":-2.623305,"marketCap":263263385},{"date":"2024-11-15","current":-3.203547,"twenty":-8.940175,"median":-4.325468,"eighty":-2.662723,"marketCap":246599464},{"date":"2024-11-22","current":-2.604905,"twenty":-8.932537,"median":-4.26416,"eighty":-2.595709,"marketCap":200517746},{"date":"2024-11-29","current":-3.066021,"twenty":-8.928026,"median":-4.259671,"eighty":-2.614613,"marketCap":236013123},{"date":"2024-12-06","current":-2.604905,"twenty":-8.923923,"median":-4.207872,"eighty":-2.614613,"marketCap":200517746},{"date":"2024-12-13","current":-2.839508,"twenty":-8.917768,"median":-4.16553,"eighty":-2.614613,"marketCap":218576797},{"date":"2024-12-20","current":-2.706027,"twenty":-8.8963,"median":-4.154189,"eighty":-2.637264,"marketCap":208301820},{"date":"2024-12-27","current":-2.503783,"twenty":-8.857064,"median":-4.126009,"eighty":-2.604905,"marketCap":192733672},{"date":"2025-01-03","current":-2.301538,"twenty":-8.828924,"median":-4.121357,"eighty":-2.580635,"marketCap":177165524},{"date":"2025-01-10","current":-2.467379,"twenty":-8.817668,"median":-4.100421,"eighty":-2.555478,"marketCap":189931405},{"date":"2025-01-17","current":-2.24491,"twenty":-8.807508,"median":-4.025877,"eighty":-2.519962,"marketCap":172806442},{"date":"2025-01-24","current":-2.301538,"twenty":-8.76475,"median":-3.953642,"eighty":-2.506562,"marketCap":177165524},{"date":"2025-01-31","current":-2.341987,"twenty":-8.689771,"median":-3.897682,"eighty":-2.501108,"marketCap":180279153},{"date":"2025-02-07","current":-2.633219,"twenty":-8.653752,"median":-3.846721,"eighty":-2.484886,"marketCap":202697286},{"date":"2025-02-14","current":-2.168057,"twenty":-8.650938,"median":-3.812237,"eighty":-2.43502,"marketCap":166890546},{"date":"2025-02-21","current":-2.366257,"twenty":-8.600298,"median":-3.772659,"eighty":-2.406705,"marketCap":182147331},{"date":"2025-02-28","current":-2.159968,"twenty":-8.48149,"median":-3.756949,"eighty":-2.381419,"marketCap":166267820},{"date":"2025-03-07","current":-2.228731,"twenty":-8.385148,"median":-3.728335,"eighty":-2.339036,"marketCap":171560990},{"date":"2025-03-14","current":-2.050756,"twenty":-8.321322,"median":-3.717675,"eighty":-2.301538,"marketCap":157861020},{"date":"2025-03-21","current":-2.07907,"twenty":-8.281473,"median":-3.705636,"eighty":-2.273606,"marketCap":160040561},{"date":"2025-03-28","current":-1.026355,"twenty":-8.238408,"median":-3.694109,"eighty":-2.254618,"marketCap":79005729},{"date":"2025-04-04","current":-0.638269,"twenty":-8.18799,"median":-3.67391,"eighty":-2.248131,"marketCap":51416427},{"date":"2025-04-11","current":-0.595459,"twenty":-8.140028,"median":-3.645441,"eighty":-2.242483,"marketCap":47967764},{"date":"2025-04-17","current":-0.719999,"twenty":-8.116132,"median":-3.63581,"eighty":-2.239145,"marketCap":58000238}],"updateTime":1745099133953}}}